Dose Proportionality and the Effects of Food on Bioavailability of an Immediate-Release Oxycodone Hydrochloride Tablet Designed to Discourage Tampering and Its Relative Bioavailability Compared With a Marketed Oxycodone Tablet Under Fed Conditions: A Single-Dose, Randomized, Open-Label, 5-Way Crossover Study in Healthy Volunteers

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1601-1612

  Bass, Almasa ^a   Stark, Jeffrey G ^b   Pixton, Glenn C ^a   Sommerville, Kenneth W ^a   Zamora, Cynthia A ^c   Leibowitz, Mark ^c   Rolleri, Robert ^a  

^a PFIZER INC   (United States)

^b Worldwide Clinical Trials Drug Development Solutions   (United States)

^c Worldwide Clinical Trials Drug Development Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAT; NALTREXONE; OXYCODONE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CALORIC INTAKE; CLINICAL EVALUATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG MARKETING; DRUG RELEASE; DRUG SAFETY; FEMALE; FLATULENCE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MEAL; NAUSEA; NORMAL HUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OXYCODONE; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84863821865     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.05.009     Document Type: Article

References (27)

1. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658 Substance Abuse and Mental Health Services Administration, Accessed November 1, 2011. http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.htm.
2. Governale L. Outpatient prescription opioid utilization in the US, years 2000-2009 Accessed December 16, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM220950.pdf.
3. RADARS system data indicate immediate release opioids responsible for higher proportion of misuse, abuse and diversion than extended release opioids. RADARS System News 2009, 4:1. Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS®) System.
4. McCabe S.E., Cranford J.A., Boyd C.J., Teter C.J. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007, 32:562-575.
5. Hays L.R. A profile of OxyContin addiction. J Addict Dis 2004, 23:1-9.
6. Hays L., Kirsh K.L., Passik S.D. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw 2003, 1:423-428.
7. Young A.M., Havens J.R., Leukefeld C.G. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct J 2010, 7:24.
8. Trends and statistics National Institutes of Health, National Institute on Drug Abuse, Accessed December 16, 2011. http://www.drugabuse.gov/drugpages/stats.html.
9. Oxecta [prescribing information] June 2011, King Pharmaceuticals, Bristol, TN, Accessed April 6, 2012. http://labeling.pfizer.com/ShowLabeling.aspx?id=620.
10. Aversion Technology Acura Pharmaceuticals, Inc., Accessed April 10, 2012. http://acurapharm.com/research-development/aversion-technology/.
11. Coleman J.J., Schuster C.R., DuPont R.L. Reducing the abuse potential of controlled substances. Pharmaceutical Medicine 2010, 24:21-36.
12. Rolleri R.L., Faulknor J.Y., Schoedel K.A., et al. Intranasal abuse potential of immediate-release oxycodone HCl formulated to deter intranasal abuse (IRO-A) Poster presented at: 73rd Annual Meeting of the College on Problems of Drug Dependence; June 18-23, 2011; Hollywood, Fla, Accessed April 4, 2012. http://www.cpdd.vcu.edu/Pages/Meetings/CPDD11AbstractBook.pdf.
13. Leibowitz M.T., Zamora C.A., Brzeczko A.W., Stark J.G. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-A with niacin, and oxycodone hydrochloride (Roxicodone) in healthy adults under fasting conditions. Am J Ther 2012 Feb 18, [Epub ahead of print].
14. ICH Topic E6 (R1) Guideline for Good Clinical Practice International Conference on Harmonisation, 1996, Accessed April 6, 2012. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
15. Guidance for industry: food-effect bioavailability and fed bioequivalence studies US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Accessed April 16, 2012. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.pdf.
16. Draft guidance on oxycodone hydrochloride US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Accessed April 16, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194657.pdf.
17. Gibaldi M., Perrier D. Noncompartmental Analysis Based on Statistical Moment Theory. Pharmacokinetics 1982, 409. Marcel Dekker, Inc, New York, NY. 2nd ed.
18. Chow S.-C., Liu J.-P. Transformation and analysis of individual subject ratios. Design and Analysis of Bioavailability and Bioequivalence Studies 2000, 161. Marcel Dekker, Inc, New York, NY. 2nd ed.
19. Guidance for industry: statistical approaches to establishing bioequivalence January 2001, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md, Accessed April 16, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070244.pdf.
20. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations March 2003, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md, Accessed April 16, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.
21. Chow S.-C., Liu J.-P. Statistical methods for average bioavailability. Design and Analysis of Bioavailability and Bioequivalence Studies 2000, 98. Marcel Dekker, Inc, New York, NY. 2nd ed.
22. Smith B.P., Vandenhende F.R., DeSante K.A., et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000, 17:1278-1283.
23. Hummel J., McKendrick S., Brindley C., French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 2009, 8:38-49.
24. Benziger D.P., Kaiko R.F., Miotto J.B., et al. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci 1996, 85:407-410.
25. Roxicodone [prescribing information] 2009, Xanodyne Pharmaceuticals, Inc, Newport, KY, Accessed April 6, 2012. http://www.xanodyne.com/pdf/Roxicodone-5mg20mg-orals-tablet.pdf.
26. Berg B.J., Pettinati H.M., Volpicelli J.R. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf 1996, 15:274-282.
27. Garbutt J.C. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 2010, 16:2091-2097.